Panuveitis clinical trials
The registry lists 39 studies for Panuveitis across more than 10 countries. 4 are recruiting or about to start. 11 of them are mainly about Panuveitis (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-09. Counting its 5 narrower conditions too, such as Behcet Syndrome: 248 studies, 56 open.
Get an email when these change. Save the Panuveitis studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Novartis Pharmaceuticals (7) · Clearside Biomedical, Inc. (5) · Lux Biosciences, Inc. (3) · XOMA (US) LLC (3) · Novartis (2) · AbbVie (2) · Sirion Therapeutics, Inc. (2) · The New York Eye & Ear Infirmary (1)
What is being tested here
Drugs under test in Panuveitis studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Tulisokibart | 1 | 0 | 1 |
| Secukinumab | 0 | 6 | 7 |
| Triamcinolone Acetonide | 0 | 2 | 3 |
| Triamcinolone | 0 | 2 | 3 |
| Voclosporin | 0 | 3 | 3 |
| Adrenocorticotropic Hormone | 0 | 0 | 2 |
| Difluprednate | 0 | 2 | 2 |
| Ustekinumab | 0 | 0 | 1 |
| Tesidolumab | 0 | 0 | 1 |
| Sotrastaurin | 0 | 0 | 1 |
Drug classes tested here Corticosteroids 7
Who these studies take
Of the 3 Panuveitis studies recruiting now, 2 (67%) set no upper age limit and 0 (0%) stop at 75 or younger. 1 (33%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 2 (67%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 1 (33%) | 1 (33%) |
| 18 | 3 (100%) | 3 (100%) |
| 30 | 3 (100%) | 3 (100%) |
| 40 | 3 (100%) | 3 (100%) |
| 50 | 3 (100%) | 3 (100%) |
| 65 | 3 (100%) | 3 (100%) |
| 75 | 3 (100%) | 3 (100%) |
| 85 | 2 (67%) | 2 (67%) |
Across all 39 studies, recruiting or not: 10% stop at 75 or younger and 3% at 65; 21% take children; 0% are for women only and 0% for men only; 5% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
What changed recently
From the registry's own updates since Oct 11, 2026.
Started recruiting1
Newly registered1
- Efficacy and Safety of Adalimumab for the Treatment of Ocular InflammationNov 3, 2026NCT07913750
Studies
Recruiting first, then most recently updated. Showing 39 of 39. search them.
- Efficacy and Safety of Adalimumab for the Treatment of Ocular InflammationNot yet recruitingNCT07913750Not applicable1 country
- A Clinical Trial Of Tulisokibart In Participants With Active, Non-Infectious Uveitis (MK-7240-019)RecruitingNCT07861074Phase 21 country
- Pathogen Detection in Infectious UveitisRecruitingNCT045216731 country
- Ixekizumab for the Management of Refractory Non-Infectious Uveitis: A Proof-of-Concept StudyRecruitingNCT06085079Phase 41 country
- A Study of REGN7041 for Active Noninfectious Uveitis in Adult ParticipantsTerminatedNCT07218770Phase 1/21 country
- Ozurdex Monotherapy TrialWithdrawnNCT05101928Phase 41 country
- A Phase I/IIa Study for the Treatment of Uveitis With IontophoresisWithdrawnNCT00499551Phase 1/21 country
- Ocular Sarcoidosis Open Label Trial of ACTHAR GelCompletedNCT02725177Not applicable1 country
- Intravitreal Sirolimus as Therapeutic Approach to UveitisWithdrawnNCT01280669Phase 21 country
- Safety and Effectiveness of Acthar Gel for Inflammation of the Eye's Uvea (Middle Layer)TerminatedNCT03656692Phase 41 country
- Post-marketing Surveillance Study of Adalimumab (Humira®) for Non-infectious Intermediate, Posterior, or Panuveitis PatientsCompletedNCT033391021 country
- Suprachoroidal Injection of CLS-TA in Patients With Non-infectious UveitisCompletedNCT03097315Phase 31 country
- MAGNOLIA: Extension Study of Patients With Non-infectious Uveitis Who Participated in CLS1001-301CompletedNCT029520012 countries
- Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious UveitisCompletedNCT02595398Phase 33 countries
- Ustekinumab (STELARA) for the Treatment of Active Sight-Threatening Uveitis (STAR Study)CompletedNCT02911116Phase 21 country
- Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat UveitisCompletedNCT01789320Phase 1/21 country
- Impact of Humira® Therapy on Ocular Inflammation, Selected Health Care Resource Utilization and Patient Reported Outcomes in Patients With Active Non-infectious Intermediate, Posterior and Panuveitis in Routine Clinical PracticeCompletedNCT0315524312 countries
- Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious UveitisCompletedNCT02255032Phase 21 country
- Safety,Tolerability and Efficacy of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, posterior-or Panuveitis ,CompletedNCT01526889Phase 22 countries
- Safety, Tolerability, and Efficacy of AEB071 in the Treatment of UveitisCompletedNCT00615693Phase 21 country
- Extension Study to Assess Safety and Efficacy of AIN457 in Patients With Active Non-infectious UveitisWithdrawnNCT01103024Phase 35 countries
- Safety and Efficacy Study of a FAI Insert in Subjects With Chronic Non-infectious Posterior UveitisCompletedNCT02746991Phase 31 country
- Sirolimus as Therapeutic Approach to UveitisCompletedNCT00908466Phase 11 country
- Interferon-alpha2a Versus Cyclosporin A for Severe Ocular Behcet's Disease (INCYTOB)CompletedNCT00167583Phase 31 country
- Safety and Efficacy of AIN457 in Noninfectious UveitisCompletedNCT00685399Phase 22 countries
- Safety and Efficacy Study of Gevokizumab to Treat Non-infectious Uveitis Controlled With Systemic TreatmentTerminatedNCT01747538Phase 322 countries
- Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious UveitisTerminatedNCT01684345Phase 322 countries
- Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious UveitisTerminatedNCT01090310Phase 38 countries
- Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious UveitisTerminatedNCT01032915Phase 310 countries
- Safety and Efficacy of AIN457 in Patients With Active Non-infectious UveitisTerminatedNCT01095250Phase 313 countries
- An Open-label, Rollover Study Providing Continued Dosing of Gevokizumab in Order to Assess Long-term Gevokizumab Safety DataTerminatedNCT02258854Phase 31 country
- Phase III Study in Refractory Behcet's DiseaseCompletedNCT00995709Phase 317 countries
- Study to Evaluate the Long Term Use of Treatment With AIN457 for UveitisWithdrawnNCT01327664Phase 3
- A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-UveitisCompletedNCT00404612Phase 37 countries
- A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active Non-infectious Anterior UveitisCompletedNCT00404885Phase 37 countries
- A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-UveitisCompletedNCT00404742Phase 37 countries
- Quality of Life and Visual Function in Uveitis PatientsStatus unknownNCT004073161 country
- Study of Difluprednate Ophthalmic Emulsion in the Treatment of UveitisCompletedNCT00406887Phase 3
- Study of Difluprednate Ophthalmic Emulsion in the Treatment of Severe UveitisCompletedNCT00407056Phase 3